Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Folia Med (Plovdiv) ; 54(1): 5-11, 2012.
Article in English | MEDLINE | ID: mdl-22908824

ABSTRACT

Ventilator-associated pneumonias have been estimated to be the second most common nosocomial infections among children treated in intensive care units. They occur in mechanically ventilated patients through intubation tube or tracheostomy, the inflammation usually involving the lung parenchyma. The ventilator-associated pneumonia is associated with a longer antibiotic treatment, greater duration of mechanical ventilation (MV) and higher mortality rates in children. The condition is also associated with a higher cost of the treatment. This paper reviews and comments in detail the criteria formulated by the National Nosocomial Infection Surveillance (NNSI) and the Centers for Disease Control and Prevention (CDC) for diagnosis of ventilator-associated pneumonias in children. The disease etiology is associated with the typical causes of nosocomial infections in this age: P. aeruginosa, E. coli and K. pneumoniae. The pathogenesis of the condition is inadequately studied but the aspiration of gastric contents and immune deficiency are proven risk factors. Two mechanisms have a major role in the development of the disease--micro-aspiration of gastric contents and colonization of the lower airways with pathogens.


Subject(s)
Pneumonia, Ventilator-Associated/diagnosis , Pneumonia, Ventilator-Associated/etiology , Child , Humans , Radiography, Thoracic , Risk Factors
2.
Folia Med (Plovdiv) ; 54(1): 12-8, 2012.
Article in English | MEDLINE | ID: mdl-22908825

ABSTRACT

Ventilator-associated pneumonia (VAP) is the second most common nosocomial infection among children treated in intensive care units. The risk factors for developing this condition are generated by the patient's bedside conditions, the equipment used and the specific treatment administered to the child. Prophylaxis of VAP should necessarily include all measures that have been proven to be efficient in this respect such as rigorous hygiene control of hands and protective clothing of attending staff, changing breathing circuits of ventilators only if they malfunction or if they are visibly contaminated, preference of orotracheal intubation (instead of nasotracheal intubation) and use of endotracheal tubes with dorsal lumens to allow respiratory secretions to drain, and introduction of a uniform approach to patient care and staff training. Prophylaxis of the microbial colonization in children by antibiotics does not reduce the incidence of VAP-causing poly-resistant bacteria. Therapeutic management includes early initiation of broad spectrum empirical antibiotic therapy, the right choice of antibiotic requiring regular monitoring and good knowledge of the antibiotics sensitivity of the most common microbial isolates in the ward.


Subject(s)
Pneumonia, Ventilator-Associated/prevention & control , Pneumonia, Ventilator-Associated/therapy , Anti-Bacterial Agents/therapeutic use , Child , Humans
3.
Folia Med (Plovdiv) ; 54(4): 37-44, 2012.
Article in English | MEDLINE | ID: mdl-23441468

ABSTRACT

AIM: To study the development of children with selectively treated cytomegalovirus infection. PATIENTS AND METHODS: We studied prospectively a risk group of 12 children with cytomegalovirus infection. These children were diagnosed by serological screening in the first three months after birth and are defined as congenital and perinatal infections. Thirteen infants with no serological evidence of previous or present cytomegalovirus infection at 4-12 months of age were used as controls. Ganciclovir in a dose of 10-15 mg/kg/day for at least 2 weeks followed by 5-7.5 mg/kg/day administered intravenously for at least 2 weeks more was given to 4 children from the risk group with PCR confirmed cytomegalovirus infection: to one with suspected congenital infection that presented with encephalitis, to two children with abnormal auditory evoked potentials (AEPs) and other non-neurological symptoms of a suspected congenital infection, and to one child with proven congenital infection with systemic manifestations. There was no infant with cytomegalic inclusion disease in the study. All other children in the risk group that had clinically manifested infection received isoprinosine in a dose of 50 mg/kg for one month. RESULTS: Psychomotor development delay at age three was found in two children from the risk group and in one child in the control group. There was no difference between the two groups regarding the frequency of paroxysmal events, sensory deficiency or frequent illnesses. CONCLUSIONS: The prognosis in cases of cytomegalovirus infection diagnosed at three years of age and treated selectively can be similar to that in infection free 3-year-old children (if there are no cases of CMV inclusion disease).


Subject(s)
Antiviral Agents/adverse effects , Child Development/drug effects , Cytomegalovirus Infections/drug therapy , Ganciclovir/adverse effects , Psychomotor Disorders/chemically induced , Psychomotor Performance/drug effects , Antiviral Agents/therapeutic use , Child, Preschool , Clinical Protocols , Cytomegalovirus/genetics , Cytomegalovirus/immunology , Cytomegalovirus Infections/complications , Cytomegalovirus Infections/congenital , Cytomegalovirus Infections/diagnosis , Ganciclovir/therapeutic use , Humans , Infant , Infant, Newborn , Injections, Intravenous , Inosine Pranobex/adverse effects , Inosine Pranobex/therapeutic use , Perinatal Care , Prognosis , Prospective Studies , Psychomotor Disorders/diagnosis , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...